Progressive non-fluent aphasia

This early-stage trial tests an oral drug called verdiperstat in 64 people with semantic variant primary progressive aphasia (svPPA), a rare dementia that affects language. The study is double-blind and placebo-controlled, meaning some participants get the drug and some get a pla…

This early-stage trial tests a gene therapy called PBFT02 for frontotemporal dementia (FTD) in people with specific genetic mutations. The therapy delivers a working copy of the GRN gene directly into the brain. The study involves 30 adults and primarily checks for safety and sid…

This study tests a drug called neflamapimod in 20 people with a language disorder called nonfluent variant primary progressive aphasia (nfvPPA). The goal is to see if the drug is safe and if it can improve language symptoms. Participants will receive either the drug or a placebo …

This study tests two types of speech therapy for people with primary progressive aphasia, a brain disorder that slowly destroys language skills. Sixty participants will work on word retrieval or script practice with a clinician and at home. Researchers will measure changes in com…

This study tests a speech-language telerehabilitation program for people with primary progressive aphasia (PPA), a dementia that slowly destroys language abilities. The program includes online therapy sessions and care partner training. Researchers will enroll 21 participants to …

This study tracks a protein called neurofilament light chain in the blood of 342 people who carry genetic mutations linked to frontotemporal dementia (FTD). Participants provide blood samples every three months for three years, often from home. The goal is to see if this biomarke…

This study uses advanced MRI scans and genetic tests to track how neurodegenerative diseases like frontotemporal dementia and ALS spread across the brain's network. Researchers will follow 645 participants, including patients, family members, and healthy controls, for up to 2 yea…

This study is testing whether wearable sensors can reliably monitor movement problems in people with progressive supranuclear palsy (PSP) and related frontotemporal disorders. About 60 participants will wear pendant-like devices for 12 months to track their activity. The goal is …

This study aims to learn more about diseases that affect the brain, such as Parkinson's disease and different types of dementia. Researchers will follow 500 adults with symptoms of these conditions over time, using brain scans and genetic tests to see how the diseases progress. T…

This observational study looks at how brain inflammation contributes to frontotemporal lobar degeneration (FTLD), a group of disorders that cause dementia. Researchers will use advanced brain scans, blood tests, and spinal fluid analysis in 110 participants to find biomarkers tha…